Frederick Munschauer, MD
At the 2016 CMSC Annual Meeting, Dr. Munschauer discussed the results of three studies that used real-world data to look at relapse rates, outpatients resource use, and costs related to patients taking subcutaneous interferon beta-1a as compared with other MS therapies.
Paulo Fontoura, MD, PhDPublish date: October 5, 2016
Harold Moses Jr, MDPublish date: August 8, 2016
Peter Chin, MDPublish date: July 18, 2016
VIDEO: Novel tools measure disease progression in MSPublish date: February 25, 2016
Immunopathogenesis, diagnosis, and treatment of MS